Noah Goodman, Chief Business Officer of Kymera Therapeutics, Inc. (NASDAQ:KYMR), completed a sale of 5,670 shares of common stock on April 9, 2026. Prices for those shares ranged from $86.618 to $87.1109, producing proceeds of approximately $500,582.
The transaction appears in a Form 4 filing with the Securities and Exchange Commission. The filing also shows Goodman sold an additional 4,500 shares on April 9 and April 10 at prices between $87.35 and $89.0, yielding roughly $397,200 in total. The filings state these sales were executed under a pre-arranged Rule 10b5-1 trading plan.
On the same day as the initial sale, April 9, Goodman exercised stock options to acquire 2,500 shares at an exercise price of $21.05, for a total exercise cost of $52,625. The Form 4 filing links the option exercise and subsequent sales to the 10b5-1 plan that governed the timing of the trades.
The insider sales were recorded while Kymera's shares were trading near $85.09. According to InvestingPro data cited in the filings, Kymera's stock has climbed about 290% over the past year. InvestingPro's Fair Value analysis, as noted in the filing, indicates that the biotechnology company, which is valued at approximately $7 billion, appears overvalued under that assessment.
Alongside the disclosures about insider transactions, Kymera has reported recent corporate and clinical developments. Gilead Sciences exercised its option to exclusively license KT-200, an oral CDK2 molecular glue degrader, triggering a $45 million milestone payment to Kymera.
Analyst coverage remains active. H.C. Wainwright reiterated a buy rating and set a $134 price target after meeting with Kymera management to discuss ongoing trials. Stephens raised its price target to $100 while maintaining an Overweight rating following Kymera's fourth-quarter and full-year 2025 financial results and business update. Morgan Stanley adjusted its target downward to $123 but also kept an Overweight rating, citing continued progress in Kymera's degrader pipeline.
Kymera has said it plans to present data from the KT-621 BroADen Phase 1b clinical trial in patients with atopic dermatitis at the American Academy of Dermatology 2026 Annual Meeting. The series of insider transactions, analyst updates, partnership milestone and planned trial data presentation reflect ongoing activity across Kymera's pipeline and corporate agenda.